Advanced Proteome Therapeutics (TSXV:APC.H) EBIT: C$-2.93 Mil (TTM As of Apr. 2023)


What is Advanced Proteome Therapeutics EBIT?

Advanced Proteome Therapeutics TSXV:APC.H EBIT is C$-2.93 Mil as of Apr. 2023.

Advanced Proteome Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Apr. 2023 was C$-2.02 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2023 was C$-2.93 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Advanced Proteome Therapeutics's annualized ROC % for the quarter that ended in Apr. 2023 was -612.12%. Advanced Proteome Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2023 was -80,800.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Advanced Proteome Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2023 was -1,502.56%.

Advanced Proteome Therapeutics  (TSXV:APC.H) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Advanced Proteome Therapeutics's annualized ROC % for the quarter that ended in Apr. 2023 is calculated as:

ROC % (Q: Apr. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2023 ) + Invested Capital (Q: Apr. 2023 ))/ count )
=-0.808 * ( 1 - 0% )/( (0.223 + 0.041)/ 2 )
=-0.808/0.132
=-612.12 %

where

Invested Capital(Q: Jan. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.438 - 1.432 - ( 0.392 - max(0, 1.636 - 0.419+0.392))
=0.223

Invested Capital(Q: Apr. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.085 - 0.073 - ( 0.053 - max(0, 0.113 - 0.084+0.053))
=0.041

Note: The Operating Income data used here is four times the quarterly (Apr. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Advanced Proteome Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2023  Q: Apr. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.08/( ( (0.019 + max(-1.405, 0)) + (0.001 + max(-0.053, 0)) )/ 2 )
=-8.08/( ( 0.019 + 0.001 )/ 2 )
=-8.08/0.01
=-80,800.00 %

where Working Capital is:

Working Capital(Q: Jan. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.027) - (1.432 + 0 + 0)
=-1.405

Working Capital(Q: Apr. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.018 + 0 + 1.3877787807814E-17) - (0.073 + 0 + -0.002)
=-0.053

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Advanced Proteome Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Apr. 2023 )
=-2.93/0.195
=-1,502.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics EBIT Related Terms

Advanced Proteome Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics EBIT Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.08 -0.57 -0.69 -2.37 0.81

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -0.14 -0.34 -0.43 -2.02

TSXV:APC.H vs VRTX, REGN, SGEN: EBIT Comparison

For the Biotechnology subindustry, Advanced Proteome Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Proteome Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's EV-to-EBIT falls into.


Advanced Proteome Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of C$-2.93 Mil mean?
Advanced Proteome Therapeutics (TSXV:APC.H) has a EBIT of C$-2.93 Mil as of Apr. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advanced Proteome Therapeutics.
Is Advanced Proteome Therapeutics' EBIT too high?
Advanced Proteome Therapeutics' current EBIT is C$-2.93 Mil.
How does Advanced Proteome Therapeutics' EBIT compare to VRTX and REGN?
Advanced Proteome Therapeutics' EBIT of C$-2.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advanced Proteome Therapeutics. Advanced Proteome Therapeutics's current EBIT is C$-2.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (TSXV:APC.H) has a current EBIT of C$-2.93 Mil. The current EBIT is C$-2.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Advanced Proteome Therapeutics (TSXV:APC.H), the current EBIT is C$-2.93 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.